Mediwound Ltd. - (MDWD) closed at $12.07 on October 26, 2026, up 0.5% from the previous close, on volume of 83,477 shares (30-day average 85,535).
Data as of October 26, 2026.
No headlines found.
Globe Newswire (Tue, 22-Sep 7:00 AM ET)
Independent DSMB Recommends MediWound's EscharEx Phase III VALUE Study Continue Without Modification
Globe Newswire (Mon, 14-Sep 7:00 AM ET)
MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Globe Newswire (Wed, 2-Sep 7:00 AM ET)
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 13-Aug 7:00 AM ET)
MediWound to Report Second Quarter 2026 Financial Results
Globe Newswire (Wed, 29-Jul 8:00 AM ET)
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Mediwound Ltd. - trades on the NASDAQ stock market under the symbol MDWD.
As of October 27, 2026, MDWD stock price climbed to $12.44 with 90,810 million shares trading.
MDWD has a beta of 0.70, meaning it tends to be less sensitive to market movements. MDWD has a correlation of 0.05 to the broad based SPY ETF.
MDWD has a market cap of $159.67 million. This is considered a Micro Cap stock.
Last quarter Mediwound Ltd. - reported $3 million in Revenue and -$.77 earnings per share. This beat revenue expectation by $500,264 and met earnings estimates .
In the last 3 years, MDWD traded as high as $24.00 and as low as $7.45.
The top ETF exchange traded funds that MDWD belongs to (by Net Assets): IWM, IZRL, IWO, VTWO, IWC.
MDWD has underperformed the market in the last year with a return of -32.5%, while the SPY ETF gained +14.8%. In the last 3 month period, MDWD fell short of the market, returning -12.6%, while SPY returned +4.5%. However, in the most recent 2 weeks MDWD has outperformed the stock market by returning -1.0%, while SPY returned -1.0%.
MDWD support price is $11.69 and resistance is $12.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MDWD shares will trade within this expected range on the day.
